FDA Determines Regulatory Review Period for A180 Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for A180, a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce, which aims to extend the patent protection for an animal drug product.